Treatment Response
Impression
- 6MWD increased by 44 m
- NT-proBNP levels decreased by 250 ng/L
- Symptoms show mild improvement
- Current echo reveals continued RV enlargement and dysfunction and the patient remains at intermediate-risk status
Based on these results, the patient’s PAH is inadequately controlled on her current therapy. Sometimes a patient like Sophia may be referred to as having ‘stagnant’ PAH despite improvements in clinical parameters, treatment guidelines recommend escalation within 3-6 months if the patient does not reach low-risk status.
A majority of patients are in intermediate or high risk after 6 months of initial oral combination therapy
Observational studies show that outcomes are substantially worse for patients who may be stagnant in I-HR or I-LR